Articular Syndrome Characteristics in Children with Mucopolysaccharidosis Type I

Background. Mucopolysaccharidosis type I is disease from the group of lysosomal storage disease developing due to mutations in the IDUA gene. It leads to the accumulation of glycosaminoglycans (GAGs) in organs and tissues. Joints damage in this disease is systemic and progressive.

Objective. The aim of the study. Nowadays, relevant issue is to investigate the effects of various types of pathogenetic therapy on the state of the osteoarticular system in patients with severe and mild phenotypes of MPS I to prevent further progression of joint pathology.

Methods. The study included 46 patients diagnosed with “mucopolysaccharidosis type I”. 35 children had severe phenotype (Hurler syndrome) and 11 — with mild phenotypes (Hurler-Scheie and Scheie syndromes). The onset age of clinical manifestations in osteoarticular system, the state of large and small joints, and the presence of cervical stenosis according to the therapy were evaluated in these patients.

Results. The osteoarticular system pathology can be usually revealed in all patients with MPS I, in both mild and severe phenotypes. The contractures of shoulder, ulnar, wrist, and small hand joints have been revealed in most patients with Hurler syndrome, regardless of the administered therapy. Hip joints pathology was observed in children who was administered with: enzyme replacement therapy (ERT) — in 46.7% of cases, hematopoietic stem cell transplantation (HSCT) in combination with ERT — in 34.4% of cases. Patients with Hurler syndrome administered with HSCT in combination with ERT had cervical stenosis statistically significantly more rarely (p = 0.018) compared to patients treated with ERT only. Patients with Hurler syndrome who were on ERT had statistically significantly lower growth rates than patients after HSCT in combination with ERT. Lesions in ulnar, wrist, knee and small hand joints were the most common in children with mild phenotypes (in 90% of cases).

Conclusion. Combined therapy (HSCT and ERT) in patients with Hurler syndrome reduces severe manifestations in osteoarticular system, including children with a pathogenic nucleotide variant c.208C>T in a homozygous state.

1. Villoria JG, Pajares S, Lopez RM, et al. Neonatal screening for inherited metabolic diseases in 2016. Semin Pediatr Neurol. 2016;23(4):257–272. doi: 10.1016/j.spen.2016.11.001

2. Giugliani R, Muschol N, Keenan HA, et al. Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I. Arch Dis Child. 2021;106(7): 674–679. doi: 10.1136/archdischild-2020-319040

3. Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymańska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation, Osteoarthritis Cartilage. 2013; 21(12):1813–1823. doi: 10.1016/j.joca.2013.08.001

4. Poletto E, Pasqualim G, Giugliani R, et al. Worldwide distribution of common IDUA pathogenic variants. Clin Genet. 2018;94(1): 95–102. doi: 10.1111/cge.13224

5. Clarke LA, Giugliani R, Guffon N, et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin Genet. 2019;96(4):281–289. doi: 10.1111/cge.13583

6. Vashakmadze ND, Namazova-Baranova LS, et al. Diagnostic Difficulties of Mucopolysaccharidosis Type I Mild Forms: Clinical Cases. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020; 19(2):132–141. (In Russ). doi: 10.15690/vsp.v19i2.2106

7. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004;144(5 Suppl):27–34. doi: 10.1016/j.jpeds.2004.01.052

8. Galimberti C, Madeo A, Di Rocco M, Fiumara A. Muco polysaccharidoses: early diagnostic signs in infants and children. Ital J Pediatr. 2018;44(Suppl 2):133. doi: 10.1186/s13052-018-0550-5

9. Vashakmadze ND, NamazovaBaranova LS, Gevorkian AK, et al. Orthopedic Pathology in Children with Mucopolysaccharidosis Type I. Voprosy sovremennoi pediatrii — Current Pediatrics. 2016;15(6):562–567. (In Russ). doi: 1010.15690/vsp.v15i6.1652

10. Vashakmadze ND, Namazova-Baranova LS, Gevorkyan AK, et al. Skeletal system involvement in patients with mucopolysaccharidosis type I. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(4):114–120. (In Russ). doi: 10.21508/1027-4065-2016-61-4-114-120

11. Dornelles AD, Artigalás O, da Silva AA, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. PLoS ONE. 2017;12(8):e0184065. doi: 10.1371/journal.pone.0184065

12. Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology. 2002;12(9):117R–125R. doi: 10.1093/glycob/cwf066

13. Polgreen LE, Lund TC, Braunlin E, et al. Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation. Pediatr Res. 2020;87(1):104–111. doi: 10.1038/s41390-019-0541-2

14. Silveri CP, Kaplan FS, Fallon MD, et al. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop. 1991;(269):305–311.

15. Hampe CS, Wesley J, Lund TC, et al. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules. 2021;11(2):189. doi: 10.3390/biom11020189

16. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171–180. doi: 10.1016/j.ymgme.2006.08.007

17. Ferrara G, Maximova N, Zennaro F, et al. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler. Pediatr Transplant. 2014;18(3):E96–E99. doi: 10.1111/petr.12231

18. Tsukimura T, Tajima Y, Kawashima I, et al. Uptake of a recombinant human α-L-iduronidase (laronidase) by cultured fibroblasts and osteoblasts. Biol Pharm Bull. 2008;31:1691–1695. doi: 10.1248/bpb.31.1691

19. Tylki-Szymanska A, Marucha J, Jurecka A, et al. Efficacy of recombinant human α-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis. 2010;33(2):151–157. doi: 10.1007/s10545-010-9059-9

20. Gabrielli O, Clarke LA, Ficcadenti A, et al. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: The important role of early treatment. BMC Med Genet. 2016;17:19. doi: 10.1186/s12881-016-0284-4

21. Peck SH, Casal ML, Malhotra NR, et al. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses. Mol Genet Metab. 2016;118(4):232–243. doi: 10.1016/j.ymgme.2016.06.002